Just Biotherapeutics, Inc., a Seattle, WA-based organization dedicated to expanding global access to important protein therapeutics, secured $15M in Series A financing.
Backers included Merck, Lilly Asia Ventures and ARCH Venture Partners.
The company intends to use the funds to design of innovative technologies that accelerate development and low cost manufacturing of complex biotherapeutics.
Founded in 2014 and led by Jim Thomas, CEO, Just is led by an experienced team in the fields of protein, process and manufacturing sciences. The company will also focus on innovative design solutions that range from the design of better therapeutic molecules to the design of more efficient manufacturing plants.
To this end, in addition to the equity investment, Just and Merck have entered into an agreement to develop innovative technologies for lowering the cost of manufacturing biologics.
Aligned with its commitment to expand global access, it is exploring additional opportunities with LAV and ARCH to create value by use of its technologies to bring products to a broader global population, starting with China. Just also plans to apply its innovations in manufacturing technology toward production and commercialization of new products in developed markets on its own and through collaboration with future partners.